A Phase I of Olaparib With Radiation Therapy in Patients With Inflammatory, Loco-regionally Advanced or Metastatic TNBC (Triple Negative Breast Cancer) or Patient With Operated TNBC With Residual Disease
Phase of Trial: Phase I
Latest Information Update: 14 Jun 2017
At a glance
- Drugs Olaparib (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Acronyms RadioPARP
- 09 Jun 2017 Planned End Date changed from 1 May 2021 to 1 Jun 2021.
- 09 Jun 2017 Planned primary completion date changed from 1 May 2019 to 1 Jun 2019.
- 09 Jun 2017 Status changed from not yet recruiting to recruiting.